Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amoxicillin + ampicillin is a combination of two beta-lactam antibiotics from the penicillin class. Both drugs act by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins, leading to cell lysis and death. Amoxicillin and ampicillin have overlapping but distinct spectra of activity against gram-positive and some gram-negative bacteria. This combination is not a standard or widely marketed formulation; both are typically used individually or in other combinations (e.g., with beta-lactamase inhibitors). The primary indications for each include treatment of infections such as those affecting the respiratory tract, urinary tract, skin, gastrointestinal system, and certain sexually transmitted infections[3][4][9][10]. There is no evidence that this specific combination (amoxicillin + ampicillin) is approved or commonly used as a fixed-dose product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + ampicillin.